Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (NASDAQ:AAPG) presented 17 clinical updates at the EHA2026 Congress, highlighting key data on olverembatinib and lisaftoclax in CML, Ph+ ALL, CLL/SLL, AML, MDS, and CMML.
Results showed high response and MRD-negativity rates with generally manageable safety across multiple Phase Ib–III and real‑world studies.
Ascentage Pharma (NASDAQ:AAPG) reported first clinical data for MDM2‑p53 inhibitor alrizomadlin (APG-115) in pediatric solid tumors at ASCO 2026, as monotherapy and with Bcl‑2 inhibitor lisaftoclax.
The combination showed an ORR of 23.5% and DCR of 70.6% in 17 patients, with no DLTs and a manageable safety profile. Alrizomadlin is included in China’s pediatric “SPARK Plan” and remains investigational, not FDA approved.
Ascentage Pharma (NASDAQ:AAPG; HKEX:6855) reported Phase Ib data on olverembatinib (HQP1351) plus blinatumomab in relapsed/refractory Ph+ BCP-ALL and CML-LBP at ASCO 2026.
In this global study, 91% (10/11) achieved CR/CRi, 67% (8/12) reached BCR::ABL1 PCR ≤0.01%, and 80% (8/10) achieved MRD negativity ≤0.01%. Most adverse events were grade 1–2 and manageable.
Ascentage Pharma (NASDAQ:AAPG) reported updated Phase II data for olverembatinib (HQP1351) as second-line therapy in chronic-phase chronic myeloid leukemia (CML-CP) at ASCO 2026.
Among 42 evaluable patients, complete cytogenetic response reached 91.3% and major molecular response 60.9% at cycle 24, with a generally manageable safety profile.
Ascentage Pharma (NASDAQ:AAPG) reported new clinical data from six trials featuring olverembatinib, lisaftoclax, and alrizomadlin at ASCO 2026. Three abstracts received rapid oral slots and three poster presentations, covering leukemia, pediatric solid tumors, SDH-deficient tumors, and two ongoing global phase 3 registrational studies.
Ascentage Pharma (NASDAQ:AAPG; HKEX:6855) will present 17 clinical advances at the 31st European Hematology Association (EHA2026) Congress in Stockholm from June 11–14, 2026, including 8 posters.
Data cover ongoing studies of Olverembatinib (HQP1351) and Lisaftoclax (APG-2575), both approved in China but not yet FDA-approved in the US.
Ascentage Pharma (NASDAQ:AAPG), a global commercial-stage biopharma company focused on oncology, will participate in three upcoming investor conferences in May and June 2026.
Management will hold one-on-one meetings, a fireside chat, and a presentation, with webcasts available via the company’s Investor Relations Events page.
Ascentage Pharma (NASDAQ: AAPG) will present six clinical abstracts at the ASCO 2026 Annual Meeting (May 29–June 2, 2026), including three rapid oral presentations and three poster presentations across hematologic and pediatric oncology.
Highlights include data on olverembatinib (HQP1351), lisaftoclax (APG-2575) and alrizomadlin (APG-115), ongoing phase 3 registrational trials (POLARIS-2, GLORA), and presentations covering leukemia, sarcoma, CLL/SLL, and pediatric relapsed/metastatic sarcomas.
Ascentage Pharma (NASDAQ: AAPG) will present four preclinical posters at AACR 2026 (April 17–22, 2026) highlighting combination strategies for Olverembatinib (HQP1351), APG-2449 and APG-5918. Key takeaways: Olverembatinib shows synergy with chemotherapy and BTK inhibition; APG-2449 enhances BRAF-targeted therapy; APG-5918 primes SCLC for topoisomerase I inhibitors.
These findings aim to inform clinical development and complement ongoing registrational trials while addressing resistance mechanisms across hematologic and solid tumors.
Ascentage Pharma (NASDAQ: AAPG) reported unaudited 2025 results: revenue US$82.1M (-41.5% YoY) and a loss of US$177.7M. Product sales rose as Olverembatinib reached US$62.2M (+80.6%) and Lisaftoclax generated US$10.1M after its July launch.
R&D was US$162.7M (+20.1%), selling/distribution US$50.6M (+80.4%), and cash was US$353.2M following 2025 equity offerings. Nine registrational Phase III trials are underway, several cleared by FDA and EMA.